ResMed Inc.
RMD Healthcare Medical - Instruments & Supplies NYSE
$252.87
$-2.45 (-0.96%)
Open: $253.15 | High: $253.26 | Low: $248.13 | Prev Close: $255.32
Market Cap: $36.91B
Volume: 754K | Avg: 1.1M
Last updated: March 09, 2026 at 02:04 AMFeatured In
This stock appears in the following dashboards:
Options Activity for RMD
Options Screener Data
| Type | Strike | Expiration | Premium | Premium Yield | Call Vol | Put Vol | P/C Ratio | Rating |
|---|---|---|---|---|---|---|---|---|
| N/A | $N/A | N/A | $N/A | N/A% | N/A | N/A | N/A | N/A/10 |
Puts/Calls Activity
| Type | Strike | Expiration | Premium | Volume | ROI % | Breakeven | Delta |
|---|---|---|---|---|---|---|---|
| N/A | $N/A | N/A | $N/A | N/A | N/A% | $N/A | N/A |
Investment Rating
Buy
Overall Score: 80/100
Rating Breakdown:
Stock Score Analysis
Stock Score: 647
Comprehensive Quality Assessment
Component Breakdown:
Valuation Metrics
| P/E Ratio | 25.26 |
| P/B Ratio | 5.86 |
| P/S Ratio | 6.84 |
| EPS | $10.01 |
| Beta | 0.89 |
| Shares Outstanding | 145.97M |
| 52-Week High | $293.81 |
| 52-Week Low | $199.92 |
| SMA 50 | $254.87 |
| SMA 200 | $260.69 |
| Dividend Yield | 0.92% |
| Annual Dividend | $2.33 |
| Next Earnings | April 30, 2026 09:00 PM ET |
Financial Ratios
| Gross Margin | 61.0% |
| Operating Margin | 33.8% |
| Net Margin | 27.5% |
| ROE | 24.8% |
| ROA | 17.5% |
| Debt/Equity | 0.16 |
| Current Ratio | 3.06 |
| Quick Ratio | 2.32 |
Balance Sheet
| Total Assets | $8.17B |
| Total Liabilities | $2.21B |
| Total Equity | $5.97B |
|
|
|
| Cash | $1.21B |
| Total Debt | $851.81M |
| Net Debt | $-357,637,000 |
Income Statement
| Revenue | $5.15B |
| Gross Profit | $3.05B |
| Operating Income | $1.69B |
| Net Income | $1.40B |
|
|
|
| EBITDA | $1.91B |
| Revenue/Share | $36.85 |
Cash Flow
| Operating CF | $1.75B |
| CapEx | $89.86M |
| Free Cash Flow | $1.66B |
|
|
|
| Book Value/Share | $43.15 |
| Tangible Book/Share | $19.43 |
| Equity/Share | $43.15 |
Technical Indicators
| RSI (14) | 49.11 Neutral |
| MACD |
-0.74
Signal: -0.10
|
| Volatility | 28.24% |
| Trading Signal | Bearish |
Performance & Returns
| 1 Year | -0.19% |
| Sharpe Ratio | -0.01 Poor |
| Volatility (Ann.) | 21.19% Moderate |
| RMD (1Y) | -0.19% |
| S&P 500 (1Y) | +13.03% |
| Alpha (Excess Return) | -13.22% |
Sector Comparison (Healthcare)
| Metric | RMD | Sector Avg | Percentile |
|---|---|---|---|
| P/E Ratio | 25.26 | 27.7 | 43% |
| P/B Ratio | 5.86 | -19.63 | 74% |
| ROE (%) | 24.81% | -9.76% | 76% |
| Net Margin (%) | 27.53% | 8.97% | 85% |
| Stock Score | 647 | 541.0 | 96% |
| 1Y Return (%) | -0.19 % | +8.31 % | 42% |
📊 Historical Price Analysis (Last 200 Days)
Loading chart...
Technical Analysis
| Ticker | Close | SMA 5 | SMA 8 | SMA 13 | SMA 50 | SMA 200 | RSI (14) | MACD | Volatility (%) | Volume | Signal | SMA Decision |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| RMD | $252.87 | $254.62 | $254.66 | $255.64 | $254.74 | $260.66 | 49.11 | -0.74 | 28.24% | 222463 | Strong Short | Bearish Stack |
Candlestick Patterns
There wasn't any recognizable pattern for the RMD stock
News Sentiment
| 📊 Ticker | 📰 Headline | 💭 Sentiment | 📡 Source | 🔗 URL |
|---|---|---|---|---|
| RMD | 3 Reasons Not to Sleep on ResMed Stock | Neutral | fool.com | Read More |
| RMD | ResMed Inc. (NYSE:RMD) Receives Average Recommendation of “Moderate Buy” from Analysts | Neutral | defenseworld.net | Read More |
| RMD | Dundas Partners LLP Acquires 22,933 Shares of ResMed Inc. $RMD | Neutral | defenseworld.net | Read More |
| RMD | ResMed Inc. $RMD Shares Sold by Blair William & Co. IL | Neutral | defenseworld.net | Read More |
| RMD | Disney, Toast, ServiceNow And A Health Care Stock On CNBC's 'Final Trades' | Neutral | feeds.benzinga.com | Read More |
Recent Insider Trading
| Date | Insider | Position | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-03-09 | Farrell Michael J. | director, officer: Chairman and CEO | BUY | 4991 | $146.34 | $730383 |
| 2026-03-09 | Farrell Michael J. | director, officer: Chairman and CEO | SELL | 4991 | $251.03 | $1252902 |
| 2026-03-09 | Farrell Michael J. | director, officer: Chairman and CEO | SELL | 4991 | $146.34 | $730383 |
| 2026-03-04 | FARRELL PETER C | director | SELL | 2000 | $260.22 | $520440 |
| 2026-03-02 | Sandercock Brett | officer: Chief Financial Officer | SELL | 1000 | $254.30 | $254300 |
Company Information
ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes. The company also provides AirView, a cloud-based system that enables remote monitoring and changing of patients' device settings; myAir, a personalized therapy management application for patients with sleep apnea that provides support, education, and troubleshooting tools for increased patient engagement and improved compliance; U-Sleep, a compliance monitoring solution that enables home medical equipment (HME)to streamline their sleep programs; connectivity module and propeller solutions; and Propeller portal. It offers out-of-hospital software solution, such as Brightree business management software and service solutions to providers of HME, pharmacy, home infusion, orthotics, and prosthetics services; MatrixCare care management and related ancillary solutions to senior living, skilled nursing, life plan communities, home health, home care, and hospice organizations, as well as related accountable care organizations; and HEALTHCAREfirst that offers electronic health record, software, billing and coding services, and analytics for home health and hospice agencies. The company markets its products primarily to sleep clinics, home healthcare dealers, and hospitals through a network of distributors and direct sales force in approximately 140 countries. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.
| CEO | Michael J. Farrell |
| Employees | 9980 |
| Country | US |
| IPO Date | 1995-06-02 |
| Exchange | NYSE |
| Website | https://www.resmed.com |
| Sector | Healthcare |
| Industry | Medical - Instruments & Supplies |
Similar Stocks (Healthcare - Medical - Instruments & Supplies)
Rating Metrics Explained
DCF Score (Discounted Cash Flow)
Measures the intrinsic value of the stock based on projected future cash flows. A higher score indicates the stock is undervalued relative to its DCF valuation.
ROE Score (Return on Equity)
Evaluates how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better profitability and management effectiveness.
ROA Score (Return on Assets)
Measures how efficiently a company uses its assets to generate profit. A higher ROA means better asset utilization and operational efficiency.
D/E Score (Debt-to-Equity)
Assesses the company's financial leverage and risk. Lower debt-to-equity ratios indicate less financial risk and better balance sheet health.
P/E Score (Price-to-Earnings)
Compares stock price to earnings per share. A lower P/E ratio may indicate the stock is undervalued, while a higher ratio could suggest overvaluation or growth expectations.
P/B Score (Price-to-Book)
Compares market price to book value per share. Lower P/B ratios may indicate undervaluation relative to the company's net asset value.
Rating Recommendations:
Each metric is scored on a scale of 1-5, where the scores are determined by comparing the company's performance against industry benchmarks and historical data:
-
Strong Buy (5/5): Excellent score - strong positive indicator
- The metric significantly outperforms industry averages (top 20% of companies)
- Indicates exceptional financial health or attractive valuation in that category
-
Buy (4/5): Good score - positive indicator
- Above-average performance (top 40% of companies)
- Shows strong fundamentals with room for improvement
-
Neutral (3/5): Average score - neutral indicator
- Performance in line with industry median (middle 20%)
- Neither significantly positive nor negative signal
-
Sell (2/5): Below average - negative indicator
- Below-average performance (bottom 40% of companies)
- Suggests weakness in this particular metric
-
Strong Sell (1/5): Poor score - strong negative indicator
- Significantly underperforms industry (bottom 20%)
- Indicates potential risk or overvaluation in that category